Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick F Smith

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
The Journal of Antimicrobial Chemotherapy|October 31, 2018
Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humansKashyap Patel, Carl M Kirkpatrick, Keith A Nieforth, et al.
Cancer Investigation|February 25, 2009
Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysisMilind M Javle, Gary Yang, Chumy E Nwogu, et al.
Clinical Pharmacology and Therapeutics|February 8, 2021
Model-Informed Drug Development for Anti-Infectives: State of the Art and FutureCraig R Rayner, Patrick F Smith, David Andes, et al.
Gastroenterology|January 18, 2012
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis CTom W Chu, Rohit Kulkarni, Edward J Gane, et al.
Clinical Pharmacology and Therapeutics|August 19, 2022
Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV-2Mohamed A Kamal, Andreas Kuznik, Luyuan Qi, et al.
British Journal of Clinical Pharmacology|February 9, 2017
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemicsMohamed A Kamal, Patrick F Smith, Nathorn Chaiyakunapruk, et al.
Lancet (London, England)|October 19, 2010
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialEdward J Gane, Stuart K Roberts, Catherine A M Stedman, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
The Journal of Antimicrobial Chemotherapy|October 31, 2018
Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humansKashyap Patel, Carl M Kirkpatrick, Keith A Nieforth, et al.
Cancer Investigation|February 25, 2009
Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysisMilind M Javle, Gary Yang, Chumy E Nwogu, et al.
Clinical Pharmacology and Therapeutics|February 8, 2021
Model-Informed Drug Development for Anti-Infectives: State of the Art and FutureCraig R Rayner, Patrick F Smith, David Andes, et al.
Gastroenterology|January 18, 2012
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis CTom W Chu, Rohit Kulkarni, Edward J Gane, et al.
Clinical Pharmacology and Therapeutics|August 19, 2022
Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV-2Mohamed A Kamal, Andreas Kuznik, Luyuan Qi, et al.
British Journal of Clinical Pharmacology|February 9, 2017
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemicsMohamed A Kamal, Patrick F Smith, Nathorn Chaiyakunapruk, et al.
Lancet (London, England)|October 19, 2010
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialEdward J Gane, Stuart K Roberts, Catherine A M Stedman, et al.
Pageof 7